Summary data from the U.K.’s National Joint Registry indicates that patients treated with the Conformis iTotal CR knee experienced a cumulative revision rate of 0.5% at four years vs. a 1.9% cumulative revision rate at four years, among all patients who underwent knee replacement.
The data summarized 576 iTotal procedures in 504 patients from 46 centers in the U.K. Among those treated with iTotal implants, just three (0.5%) required revision by four years.
The iTotal CR recently received a 3A rating from the U.K.’s Orthopaedic Data Evaluation Panel, reflecting strong evidence of performance over three years, including low revision rates.
Summary data from the U.K.'s National Joint Registry indicates that patients treated with the Conformis iTotal CR knee experienced a cumulative revision rate of 0.5% at four years vs. a 1.9% cumulative revision rate at four years, among all patients who underwent knee replacement.
The data summarized 576 iTotal procedures in 504 patients from...
Summary data from the U.K.’s National Joint Registry indicates that patients treated with the Conformis iTotal CR knee experienced a cumulative revision rate of 0.5% at four years vs. a 1.9% cumulative revision rate at four years, among all patients who underwent knee replacement.
The data summarized 576 iTotal procedures in 504 patients from 46 centers in the U.K. Among those treated with iTotal implants, just three (0.5%) required revision by four years.
The iTotal CR recently received a 3A rating from the U.K.’s Orthopaedic Data Evaluation Panel, reflecting strong evidence of performance over three years, including low revision rates.
Copy to clipboard 
